Actively Recruiting
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
Led by University of Rome Tor Vergata · Updated on 2025-08-01
300
Participants Needed
1
Research Sites
208 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
To define the sensibility and the specificity of increased levels of MR-proADM for early, non-invasive, diagnosis of AR and DGF after kidney and liver transplantation creating a predictive model for related complications after kidney and liver transplantation based on the pre-operative and post-operative levels of MR-proADM and by a machine learning process.
CONDITIONS
Official Title
MR-proADM as a Early Biomarker for DGF and AR in Kidney and Liver Transplantation
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Kidney transplant recipient at our Institution
- Liver transplant recipient at our Institution
You will not qualify if you...
- Re-transplantation
- Dual kidney transplantation
- Combined transplant (kidney-liver, kidney-pancreas)
- Autoimmune disease as indication to transplant
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
University of Rome Tor Vergata
Rome, Italy, 00133
Actively Recruiting
Research Team
R
Roberta Angelico, PhD FEBS
CONTACT
D
Domiziana Pedini, MD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here